Shares of Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report) were up 1.3% during trading on Monday . The stock traded as high as $1.60 and last traded at $1.55. Approximately 13,150 shares changed hands during trading, a decline of 13% from the average daily volume of 15,166 shares. The stock had previously closed at $1.53.
Medexus Pharmaceuticals Price Performance
The business’s fifty day simple moving average is $1.80 and its two-hundred day simple moving average is $1.60.
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Further Reading
- Five stocks we like better than Medexus Pharmaceuticals
- What is the S&P/TSX Index?
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Consumer Discretionary Stocks Explained
- Applied Materials Market Capitulates: Now is the Time to Buy
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
